Insights
Insights From Our Experts
Articles
Staying Ahead of the Curve in Pharmacovigilance: Inspection Metrics Report for 2023 by Egyptian Drug Authority (EDA)
In an era where patient safety and regulatory compliance are more critical than ever, staying informed about global pharmacovigilance trends is essential. The Egyptian Drug Authority (EDA) recently released its 2023 Pharmacovigilance Inspection Metrics Report, offering…
Staying Ahead of the Curve in Pharmacovigilance: ANVISA RDC No. 967/25
As the regulatory landscape continues to evolve, staying compliant with new pharmacovigilance requirements is more important than ever. Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. What You Need to Know About…
Staying Ahead of the Curve in Pharmacovigilance: Decentralized Manufacture — UK Guidelines of Good Pharmacovigilance Practices
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations and guidelines, assess their impact and recommend actions that empower professionals to update their…
Reimagining Patient Health Experiences: A New Paradigm for Transforming Lives
Traditionally, the healthcare system has approached patient care, especially for those with acute conditions and rare diseases, through a lens of sympathy, problem-solving, and normalization. The focus has often been on identifying deficits and developing tools…
Comparing Long-Term HAE Treatments: Insights from a Robust Network Meta-Analysis
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent edema attacks in various parts of the body, including the extremities, face, gastrointestinal tract, and airway. While most current treatments can help relieve acute symptoms…
Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In an EVERSANA-led discussion, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key Challenges: 3x lower net revenue…
Navigating the Final FDA SIUU Guidance: Strategic Considerations for Scientific Exchange at ASCO and Other Congresses
Posted by
Anne Marie Robertson , Tim Lewis , Susan Giacalone, MSN, BCMAS, MSL-BC on May 29, 20255/29/25
The FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU) marks a pivotal shift for pharmaceutical companies—offering new clarity and flexibility for engaging healthcare providers in compliant, science-based dialogue. In this POV, EVERSANA ONCOLOGY’s experts…
Most Favored Nation Pricing | Insights and Implications for Manufacturers
The EVERSANA MANAGEMENT CONSULTING team provides an overview of the recent developments and shares their views on the strategic implications for manufacturers. Manufacturers must act decisively to mitigate Most Favored Nation (MFN) exposure through global pricing…
Demystifying Market Access: A Must-Read for Navigating the Lab-to-Patient Journey
Market access is no longer just a final hurdle—it’s a strategic imperative that shapes how therapies reach the patients who need them most. If you’ve ever wondered what it really takes to bring a treatment from…
Webinar: Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In a recent EVERSANA webinar, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key challenges: 3x lower net…